GDNF therapy for Parkinson’s disease

References

• Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality. Neurology17, 427–442 (1967).
   PubMed Web of Science ®Google Scholar
• Albin RL, Young AB, Penney JB. The functional anatomy of basal ganglia disorders. Trends Neurosci.10, 366–375 (1989).
   Google Scholar
• Sian J, Gerlach M, Youdim MB, Riederer P. Parkinson’s disease: a major hypokinetic basal ganglia disorder. J. Neural Transm.106, 443–476 (1999).
   PubMed Web of Science ®Google Scholar
• Jellinger K. The pathology of parkinsonism. In: Movement Disorders 2. Marsden CD, Fahn S (Eds), Butterworth-Heinemann, UK, 124–165 (1987).
   Google Scholar
• Takahashi H, Wakabayashi K. The cellular pathology of Parkinson’s disease. Neuropathology21, 315–322 (2001).
   PubMed Web of Science ®Google Scholar
• Dunnett SB, Björklund A. Prospects for new restorative and neuroprotective treatments in Parkinson’s disease. Nature6738, A32–A39 (1999).
   Google Scholar
• Clough CG. Parkinson’s disease: management. Lancet337, 1324–1327 (1991).
   PubMedGoogle Scholar
• Forno LS. Pathology of Parkinson’s disease: the importance of the substantia nigra and Lewy bodies. In: Parkinson’s Disease. Stern GM (Ed). Chapman and Hall, London, UK, 185–238 (1990).
   Google Scholar
• Truong DD, Bhidayasiri R, Wolters E. Management of non-motor symptoms in advanced Parkinson disease. J. Neurol. Sci.266, 216–228 (2008).
   PubMed Web of Science ®Google Scholar
• Caballol N, Martí MJ, Tolosa E. Cognitive dysfunction and dementia in Parkinson disease. Mov. Disord.22(Suppl. 17), S358–S366 (2007).
   PubMed Web of Science ®Google Scholar
• Goldmann Gross R, Siderowf A, Hurtig HI. Cognitive impairment in Parkinson’s disease and dementia with lewy bodies: a spectrum of disease. Neurosignals16, 24–34 (2008).
   PubMedGoogle Scholar
• Fearnley JM, Lees AJ. Ageing and Parkinson’s disease: substantia nigra regional selectivity. Brain114, 2283–2301 (1991).
   PubMed Web of Science ®Google Scholar
• Marsden CD. Parkinson’s disease. Lancet335, 948–952 (1990).
   PubMed Web of Science ®Google Scholar
• Birkmayer W, Hornykiewics O. Der 1-3,4-dioxyphenylanalin (l-DOPA)-effekt bei der Parkinson-Akinesia. Klin. Wochenschr.73, 787–788 (1961).
   Google Scholar
• Hornykiewicz O. Dopamine and brain function. Pharmacol. Rev.18, 925–964 (1966).
   PubMed Web of Science ®Google Scholar
• Hauser RA, Zesiewicz TA. Advances in the pharmacologic management of early Parkinson disease. Neurologist13, 126–132 (2007).
   PubMedGoogle Scholar
• Olanow CW, Fahn S, Muenter M et al. A multicenter double-blind placebo-controlled trial of pergolide as an adjunct to Sinemet in Parkinson’s disease. Mov. Disord.9, 40–47 (1994).
   PubMed Web of Science ®Google Scholar
• Shoulson I. DATATOP: a decade of neuroprotective inquiry. Parkinson Study Group. Deprenyl And Tocopherol Antioxidative Therapy Of Parkinsonism. Ann. Neurol.44, S160–S166 (1998).
   PubMed Web of Science ®Google Scholar
• Nutt JG. Catechol-O-methyltransferase inhibitors for treatment of Parkinson’s disease. Lancet351, 1221–1222 (1998).
   PubMedGoogle Scholar
• Fahn S, Oakes D, Shoulson I et al. Levodopa and the progression of Parkinson’s disease. N. Engl. J. Med.351, 2498–2508 (2004).
   PubMed Web of Science ®Google Scholar
• Marsden CD, Parkes JD. Effects in patients with Parkinson’s disease on chronic levodopa therapy. Lancet1, 292–296 (1976).
   PubMed Web of Science ®Google Scholar
• Zesiewicz TA, Sullivan KL, Hauser RA. Levodopa-induced dyskinesia in Parkinson’s disease: epidemiology, etiology, and treatment. Curr. Neurol. Neurosci. Rep.7, 302–310 (2007).
   PubMedGoogle Scholar
• Lhermitte F, Agid Y, Signoret JL. Onset and end-of-dose levodopa-induced dyskinesias. Possible treatment by increasing the daily doses of levodopa. Arch. Neurol.35, 261–263 (1978).
   PubMedGoogle Scholar
• Mouradian MM, Juncos JL, Fabbrini G, Schlegel J, Bartko JJ, Chase TN. Motor fluctuations in Parkinson’s disease: pathogenic and therapeutic studies. Ann. Neurol.22, 475–479 (1987).
   PubMed Web of Science ®Google Scholar
• Agid Y. Levodopa: is toxicity a myth? Neurology50, 858–863 (1998).
   PubMed Web of Science ®Google Scholar
• Fahn S, the Parkinson Study Group. Does levodopa slow or hasten the rate of progression of Parkinson’s disease? J. Neurol.252(Suppl. 4), IV37–IV42 (2005).
   PubMed Web of Science ®Google Scholar
• Miyasaki JM, Martin W, Suchowersky O, Weiner WJ, Lang AE. Practice parameter: initiation of treatment for Parkinson’s disease: an evidence-based review: report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology58, 11–17 (2002).
   PubMed Web of Science ®Google Scholar
• Mierau J, Schingnitz G. Biochemical and pharmacological studies on pramipexole, a potent and selective dopamine D2 receptor agonist. Eur. J. Pharmacol.215, 161–170 (1992).
   PubMed Web of Science ®Google Scholar
• Tulloch IF. Pharmacologic profile of ropinirole: a nonergoline dopamine agonist. Neurology49(Suppl. 1), S58–S62 (1997).
   PubMed Web of Science ®Google Scholar
• LeWitt PA, Lyons KE, Pahwa R. Advanced Parkinson disease treated with rotigotine transdermal system: PREFER Study. Neurology68, 1262–1267 (2007).
   PubMed Web of Science ®Google Scholar
• LeWitt PA. Subcutaneously administered apomorphine: pharmacokinetics and metabolism. Neurology62(Suppl. 4), S8–S11 (2004).
   PubMed Web of Science ®Google Scholar
• Watts RL. The role of dopamine agonists in early Parkinson’s disease. Neurology49(1 Suppl. 1), S34–S48 (1997).
   Google Scholar
• Waters CH, Sethi KD, Hauser RA, Molho E, Bertoni JM. Zydis selegiline reduces off time in Parkinson’s disease patients with motor fluctuations: a 3-month, randomized, placebo-controlled study. Mov. Disord.19, 426–432 (2004).
   PubMed Web of Science ®Google Scholar
• Siderowf A, Stern M. Clinical trials with rasagiline: evidence for short-term and long-term effects. Neurology66(Suppl. 4), S80–S88 (2006).
   Google Scholar
• Nagatsu T, Sawada M. Molecular mechanism of the relation of monoamine oxidase B and its inhibitors to Parkinson’s disease: possible implications of glial cells. J. Neural Transm. Suppl.71, 53–65 (2006).
   PubMedGoogle Scholar
• Mizuta I, Ohta M, Ohta K et al. Selegiline and desmethylselegiline stimulate NGF, BDNF, and GDNF synthesis in cultured mouse astrocytes. Biochem. Biophys. Res. Commun.279, 751–755 (2000).
   PubMed Web of Science ®Google Scholar
• Youdim MB, Maruyama W, Naoi M. Neuropharmacological, neuroprotective and amyloid precursor processing properties of selective MAO-B inhibitor antiparkinsonian drug, rasagiline. Drugs Today (Barc.)41, 369–391 (2005).
   PubMedGoogle Scholar
• Lees AJ, Ratziu V, Tolosa E, Oertel WH. Safety and tolerability of adjunctive tolcapone treatment in patients with early Parkinson’s disease. J. Neurol. Neurosurg. Psychiatry78, 944–948 (2007).
   PubMed Web of Science ®Google Scholar
• Schuurman PR, Bosch DA. Surgical considerations in movement disorders: deep brain stimulation, ablation and transplantation. Acta Neurochir. Suppl.97, 119–125 (2007).
   PubMedGoogle Scholar
• Hamani C, Neimat JS, Lozano AM. Deep brain stimulation and chemical neuromodulation: current use and perspectives for the future. Acta Neurochir. Suppl.97, 127–133 (2007).
   PubMedGoogle Scholar
• Nagaseki Y, Shibazaki T, Hirai T et al. Long-term follow-up results of selective VIM-thalamotomy. J. Neurosurg.65, 296–302 (1986).
   PubMed Web of Science ®Google Scholar
• Schuurman PR, Bosch DA, Bossuyt PMM et al. A comparison of continuous thalamic stimulation and thalamotomy for suppression of severe tremor. N. Engl. J. Med.342, 461–468 (2000).
   PubMed Web of Science ®Google Scholar
• Lang AE, Lozano AM, Montgomery E, Duff J, Tasker R, Hutchinson W. Posteroventral medial pallidotomy in advanced Parkinson’s disease. N. Engl. J. Med.337, 1036–1042 (1997).
   PubMed Web of Science ®Google Scholar
• Vitek JL, Bakay RA, Freeman A et al. Randomized trial of pallidotomy versus medical therapy for Parkinson’s disease. Ann. Neurol.53, 558–569 (2003).
   PubMed Web of Science ®Google Scholar
• Patel NK, Heywood P, O’Sullivan K, McCarter R, Love S, Gill SS. Unilateral subthalamotomy in the treatment of Parkinson’s disease. Brain126, 1136–1145 (2003).
   PubMedGoogle Scholar
• The Deep-Brain Stimulation for Parkinson’s Disease Study Group. Deep-brain stimulation of the subthalamic nucleus or the pars interna of the globus pallidus in Parkinson’s disease. N. Engl. J. Med.345, 956–963 (2001).
   PubMedGoogle Scholar
• Volkmann J, Allert N, Voges J, Sturm V, Schnitzler A, Freund HJ. Long-term results of bilateral pallidal stimulation in Parkinson’s disease. Ann. Neurol.55, 871–875 (2004).
   PubMed Web of Science ®Google Scholar
• Anderson VC, Burchiel KJ, Hogarth P, Favre J, Hammerstad JP. Pallidal VS. subthalamic nucleus deep brain stimulation in Parkinson disease. Arch. Neurol.62, 554–560 (2005).
   PubMed Web of Science ®Google Scholar
• Limousin P, Krack P, Pollak P et al. Electrical stimulation of the subthalamic nucleus in advanced Parkinson’s disease. N. Engl. J. Med.339, 1105–1111 (1998).
   PubMed Web of Science ®Google Scholar
• Vingerhoets FJ, Villemure JG, Temperli P, Pollo C, Pralong E, Ghika J. Subthalamic DBS replaces levodopa in Parkinson’s disease: two-year follow-up. Neurology58, 396–401 (2002).
   PubMed Web of Science ®Google Scholar
• Smeding HM, Esselink RA, Schmand B et al. Unilateral pallidotomy versus bilateral subthalamic nucleus stimulation in PD – a comparison of neuropsychological effects. J. Neurol.252, 176–182 (2005).
   PubMedGoogle Scholar
• Rothlind JC, Cockshott RW, Starr PA, Marks WJ Jr. Neuropsychological performance following staged bilateral pallidal or subthalamic nucleus deep brain stimulation for Parkinson’s disease. J. Int. Neuropsychol. Soc.13, 68–79 (2007).
   PubMed Web of Science ®Google Scholar
• Berney A, Vingerhoets F, Perrin A et al. Effect on mood of subthalamic DBS for Parkinson’s disease: a consecutive series of 24 patients. Neurology59, 1427–1429 (2002).
   PubMed Web of Science ®Google Scholar
• Houeto JL, Mesnage V, Mallet L et al. Behavioural disorders, Parkinson’s disease and subthalamic stimulation. J. Neurol. Neurosurg. Psychiatry72, 701–707 (2002).
   PubMed Web of Science ®Google Scholar
• Bradford HF, Zhou J, Pliego-Rivero B, Stern GM, Jauniaux E. Neurotrophins in the pathogenesis and potential treatment of Parkinson’s disease. Adv. Neurol.80, 19–25 (1999).
   PubMedGoogle Scholar
• Ferrari G, Minozzi MC, Toffano G, Leon A, Skaper SD. Basic fibroblast growth factor promotes the survival and development of mesencephalic neurons in culture. Dev. Biol.133, 140–147 (1989).
   PubMed Web of Science ®Google Scholar
• Knusel B, Michel PP, Schwaber JS, Hefti F. Selective and nonselective stimulation of central cholinergic and dopaminergic development in vitro by nerve growth factor, basic fibroblast growth factor, epidermal growth factor, insulin and the insulin-like growth factors I and II. J. Neurosci.10, 558–570 (1990).
   PubMed Web of Science ®Google Scholar
• Park TH, Mytilineou C. Protection from 1-methyl-4-phenylpyridinium (MPP+) toxicity and stimulation of regrowth of MPP(+)- damaged dopaminergic fibers by treatment of mesencephalic cultures with EGF and basic FGF. Brain Res.599, 83–97 (1992).
   PubMedGoogle Scholar
• Hyman C, Hofer M, Barde YA et al. BDNF is a neurotrophic factor for dopaminergic neurons of the substantia nigra. Nature350, 230–232 (1991).
   PubMed Web of Science ®Google Scholar
• Miao N, Wang M, Ott JA et al. Sonic hedgehog promotes the survival of specific CNS neuron populations and protects these cells from toxic insult in vitro. J. Neurosci.17, 5891–5899 (1997).
   PubMedGoogle Scholar
• Ventrella LL. Effect of intracerebroventricular infusion of epidermal growth factor in rats hemitransected in the nigrostriatal pathway. J. Neurosurg. Sci.37, 1–8 (1993).
   PubMedGoogle Scholar
• Zeng BY, Jenner P, Marsden CD. Altered motor function and graft survival produced by basic fibroblast growth factor in rats with 6-OHDA lesions and fetal ventral mesencephalic grafts are associated with glial proliferation. Exp. Neurol.139, 214–226 (1996).
   PubMedGoogle Scholar
• Pearce RK, Collins P, Jenner P, Emmett C, Marsden CD. Intraventricular infusion of basic fibroblast growth factor (bFGF) in the MPTP-treated common marmoset. Synapse23, 192–200 (1996).
   PubMed Web of Science ®Google Scholar
• Svendsen CN, Clarke DJ, Rosser AE, Dunnett SB. Survival and differentiation of rat and human epidermal growth factor-responsive precursor cells following grafting into the lesioned adult central nervous system. Exp. Neurol.137, 376–388 (1996).
   PubMed Web of Science ®Google Scholar
• Klein RL, Lewis MH, Muzyczka N, Meyer EM. Prevention of 6-hydroxydopamine-induced rotational behavior by BDNF somatic gene transfer. Brain Res.847, 314–320 (1999).
   PubMedGoogle Scholar
• Pearce RK, Costa S, Jenner P, Marsden CD. Chronic supranigral infusion of BDNF in normal and MPTP-treated common marmosets. J. Neural Transm.106, 663–683 (1999).
   PubMedGoogle Scholar
• Tsuboi K, Shults CW. Intrastriatal injection of sonic hedgehog reduces behavioral impairment in a rat model of Parkinson’s disease. Exp. Neurol.173, 95–104 (2002).
   PubMed Web of Science ®Google Scholar
• Dass B, Iravani MM, Jackson MJ, Engber TM, Galdes A, Jenner P. Behavioural and immunohistochemical changes following supranigral administration of sonic hedgehog in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridinetreated common marmosets. Neuroscience114, 99–109 (2002).
   PubMedGoogle Scholar
• Sun M, Kong L, Wang X, Lu XG, Gao Q, Geller AI. Comparison of the capability of GDNF, BDNF, or both, to protect nigrostriatal neurons in a rat model of Parkinson’s disease. Brain Res.1052, 119–129 (2005).
   PubMed Web of Science ®Google Scholar
• Bespalov MM, Saarma M. GDNF family receptor complexes are emerging drug targets. Trends Pharmacol. Sci.28, 68–74 (2007).
   PubMed Web of Science ®Google Scholar
• Lin LF, Doherty DH, Lile JD, Bektesh S, Collins F. GDNF: a glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons. Science260, 1130–1132 (1993).
   PubMed Web of Science ®Google Scholar
• Beck KD, Valverde J, Alexi T et al. Mesencephalic dopaminergic neurons protected by GDNF from axotomy-induced degeneration in the adult brain. Nature373, 339–341 (1995).
   PubMed Web of Science ®Google Scholar
• Kearns CM, Gash DM. GDNF protects nigral dopamine neurons against 6-hydroxydopamine in vivo. Brain Res.672, 104–111 (1995).
   PubMed Web of Science ®Google Scholar
• Sauer H, Rosenblad C, Björklund A. Glial cell line-derived neurotrophic factor but not transforming growth factor b3 prevents delayed degeneration of nigral dopaminergic neurons following striatal 6-hydroxydopamine lesion. Proc. Natl Acad. Sci. USA92, 8935–8939 (1995).
   PubMed Web of Science ®Google Scholar
• Sauer H, Oertel WH. Progressive degeneration of nigrostriatal dopamine neurons following intrastriatal terminal lesions with 6-hydroxydopamine: a combined retrograde tracing and immunocytochemical study in the rat. Neuroscience59, 401–415 (1994).
   PubMed Web of Science ®Google Scholar
• Björklund A, Rosenblad C, Winkler C, Kirik D. Studies on neuroprotective and regenerative effects of GDNF in a partial lesion model of Parkinson’s disease. Neurobiol. Dis.4, 186–200 (1997).
   PubMed Web of Science ®Google Scholar
• Shults CW, Kimber T, Martin D. Intrastriatal injection of GDNF attenuates the effects of 6-hydroxydopamine. Neuroreport7, 627–631 (1996).
   PubMedGoogle Scholar
• Rosenblad C, Martinez-Serrano A, Björklund A. Intrastriatal glial cell line derived neurotrophic factor promotes sprouting of spared nigrostriatal dopaminergic afferents and induces recovery of function in a rat model of Parkinson’s disease. Neuroscience82, 129–137 (1998).
   PubMed Web of Science ®Google Scholar
• Rosenblad C, Kirik D, Devaux B, Moffat B, Phillips HS, Björklund A. Protection and regeneration of nigral dopaminergic neurons by neurturin or GDNF in a partial lesion model of Parkinson’s disease after administration into the striatum or the lateral ventricle. Eur. J. Neurosci.11, 1554–1566 (1999).
   PubMed Web of Science ®Google Scholar
• Kirik D, Rosenblad C, Björklund A. Preservation of a functional nigrostriatal dopamine pathway by GDNF in the intrastriatal 6-OHDA lesion model depends on the site of administration of the trophic factor. Eur. J. Neurosci.12, 3871–3882 (2000).
   PubMed Web of Science ®Google Scholar
• Kirik D, Georgievska B, Björklund A. Localized striatal delivery of GDNF as a treatment for Parkinson disease. Nat. Neurosci.7, 105–110 (2004).
   PubMed Web of Science ®Google Scholar
• Smith MP, Cass WA. GDNF reduces oxidative stress in a 6-hydroxydopamine model of Parkinson’s disease. Neurosci. Lett.412, 259–263 (2007).
   PubMedGoogle Scholar
• Bowenkamp KE, Hoffman AF, Gerhardt GA et al. Glial cell line-derived neurotrophic factor supports survival of injured midbrain dopaminergic neurons. J. Comp. Neurol.355, 479–489 (1995).
   PubMed Web of Science ®Google Scholar
• Winkler C, Sauer H, Lee CS et al. ShortHterm GDNF treatment provides long-term rescue of lesioned nigral dopaminergic neurons in a rat model of Parkinson’s disease. J. Neurosci.16, 7206–7215 (1996).
   PubMed Web of Science ®Google Scholar
• Kirik D, Georgievska B, Rosenblad C, Björklund A. Delayed infusion of GDNF promotes recovery of motor function in the partial lesion model of Parkinson’s disease. Eur. J. Neurosci.13, 1589–1599 (2001).
   PubMed Web of Science ®Google Scholar
• Gash DM, Zhang Z, Ovadia A et al. Functional recovery in parkinsonian monkeys treated with GDNF. Nature380, 252–255 (1996).
   PubMed Web of Science ®Google Scholar
• Oiwa Y, Nakai K, Itakura T. Histological effects of intraputaminal infusion of glial cell line-derived neurotrophic factor in Parkinson disease model macaque monkeys. Neurol. Med. Chir. (Tokyo)46, 267–275 (2006).
   PubMedGoogle Scholar
• Zhang Z, Miyoshi Y, Lapchak PA et al. Dose response to intraventricular glial cell line-derived neurotrophic factor administration in parkinsonian monkeys. J. Pharmacol. Exp. Ther.282, 1396–1401 (1997).
   PubMedGoogle Scholar
• Lawlor PA, During MJ. Gene therapy for Parkinson’s disease. Expert Rev. Mol. Med.6, 1–18 (2004).
   PubMedGoogle Scholar
• Choi-Lundberg DL, Lin Q, Chang YN et al. Dopaminergic neurons protected from degeneration by GDNF gene therapy. Science275, 838–841 (1997).
   PubMed Web of Science ®Google Scholar
• Lapchak PA, Araujo DM, Hilt DC, Sheng J, Jiao S. Adenoviral vectormediated GDNF gene therapy in a rodent lesion model of late stage Parkinson’s disease. Brain Res.777, 153–160 (1997).
   PubMed Web of Science ®Google Scholar
• Kozlowski DA, Connors B, Tillerson JL et al. Delivery of a GDNF gene into the substantia nigra after a progressive 6-OHDA lesion maintains functional nigrostriatal connections. Exp. Neurol.166, 1–15 (2000).
   PubMed Web of Science ®Google Scholar
• Choi-Lundberg DL, Lin Q, Schallert T et al. Behavioral and cellular protection of rat dopaminergic neurons by an adenoviral vector encoding glial cell line-derived neurotrophic factor. Exp. Neurol.154, 261–275 (1998).
   PubMed Web of Science ®Google Scholar
• Bilang-Bleuel A, Revah F, Colin F et al. Intrastriatal injection of an adenoviral vector expressing glial cell-line-derived neurotrophic factor prevents dopaminergic neuron degeneration and behavioral impairment in a rat model of Parkinson disease. Proc. Natl Acad. Sci. USA94, 8818–8823 (1997).
   PubMed Web of Science ®Google Scholar
• Connor B, Kozlowski DA, Schallert T, Tillerson JL, Davidson BL, Bohn MC. Differential effects of glial cell line-derived neurotrophic factor (GDNF) in the striatum and substantia nigra of the aged Parkinsonian rat. Gene Ther.6, 1936–1951 (1999).
   PubMed Web of Science ®Google Scholar
• Connor B, Kozlowski DA, Unnerstall JR et al. Glial cell line-derived neurotrophic factor (GDNF) gene delivery protects dopaminergic terminals from degeneration. Exp. Neurol.169, 83–95 (2001).
   PubMed Web of Science ®Google Scholar
• Mandel RJ, Spratt SK, Snyder RO, Leff SE. Midbrain injection of recombinant adeno-associated virus encoding rat glial cell line-derived neurotrophic factor protects nigral neurons in a progressive 6-hydroxydopamine-induced degeneration model of Parkinson’s disease in rats. Proc. Natl Acad. Sci. USA94, 14083–14088 (1997).
   PubMed Web of Science ®Google Scholar
• Kirik D, Rosenblad C, Björklund A, Mandel RJ. Long-term rAAV-mediated gene transfer of GDNF in the rat Parkinson’s model: intrastriatal but not intranigral transduction promotes functional regeneration in the lesioned nigrostriatal system. J. Neurosci.20, 4686–4700 (2000).
   PubMed Web of Science ®Google Scholar
• Georgievska B, Kirik D, Rosenblad C, Lundberg C, Björklund A. Neuroprotection in the rat Parkinson model by intrastriatal GDNF gene transfer using a lentiviral vector. Neuroreport13, 75–82 (2002).
   PubMedGoogle Scholar
• Wang L, Muramatsu S, Lu Y et al. Delayed delivery of AAVGDNF prevents nigral neurodegeneration and promotes functional recovery in a rat model of Parkinson’s disease. Gene Ther.9, 381–389 (2002).
   PubMed Web of Science ®Google Scholar
• Brizard M, Carcenac C, Bemelmans AP, Feuerstein C, Mallet J, Savasta M. Functional reinnervation from remaining DA terminals induced by GDNF lentivirus in a rat model of early Parkinson’s disease. Neurobiol. Dis.21, 90–101 (2006).
   PubMed Web of Science ®Google Scholar
• Kordower JH, Emborg ME, Bloch J et al. Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson’s disease. Science290, 767–773 (2000).
   PubMed Web of Science ®Google Scholar
• Eslamboli A, Georgievska B, Ridley RM et al. Continuous low-level glial cell line-derived neurotrophic factor delivery using recombinant adeno-associated viral vectors provides neuroprotection and induces behavioral recovery in a primate model of Parkinson’s disease. J. Neurosci.25, 769–777 (2005).
   PubMed Web of Science ®Google Scholar
• Palfi S, Leventhal L, Chu Y et al. Lentivirally delivered glial cell line-derived neurotrophic factor increases the number of striatal dopaminergic neurons in primate models of nigrostriatal degeneration. J. Neurosci.22, 4942–4954 (2002).
   PubMed Web of Science ®Google Scholar
• Lo Bianco C, Déglon N, Pralong W, Aebischer P. Lentiviral nigral delivery of GDNF does not prevent neurodegeneration in a genetic rat model of Parkinson’s disease. Neurobiol. Dis.17, 283–289 (2004).
   PubMedGoogle Scholar
• Georgievska B, Kirik D, Björklund A. Aberrant sprouting and downregulation of tyrosine hydroxylase in lesioned nigrostriatal dopamine neurons induced by long-lasting overexpression of glial cell line derived neurotrophic factor in the striatum by lentiviral gene transfer. Exp. Neurol.177, 461–474 (2002).
   PubMed Web of Science ®Google Scholar
• Do Thi NA, Saillour P, Ferrero L, Paunio T, Mallet J. Does neuronal expression of GDNF effectively protect dopaminergic neurons in a rat model of Parkinson’s disease? Gene Ther.14, 441–450 (2007).
   PubMedGoogle Scholar
• Kordower JH, Palfi S, Chen EY et al. Clinicopathological findings following intraventricular glial-derived neurotrophic factor treatment in a patient with Parkinson’s disease. Ann. Neurol.46, 419–424 (1999).
   PubMed Web of Science ®Google Scholar
• Nutt JG, Burchiel KJ, Comella CL et al. Randomized, double-blind trial of glial cell line-derived neurotrophic factor (GDNF) in PD. Neurology60, 69–73 (2003).
   PubMed Web of Science ®Google Scholar
• Lapchak PA, Jiao S, Collins F, Miller PJ. Glial cell line-derived neurotrophic factor: distribution and pharmacology in the rat following a bolus intraventricular injection. Brain Res.747, 92–102 (1997).
   PubMedGoogle Scholar
• Grondin R, Zhang Z, Yi A et al. Chronic, controlled GDNF infusion promotes structural and functional recovery in advanced parkinsonian monkeys. Brain125, 2191–2201 (2002).
   PubMed Web of Science ®Google Scholar
• Gill SS, Patel NK, Hotton GR et al. Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease. Nat. Med.9, 589–595 (2003).
   PubMed Web of Science ®Google Scholar
• Patel NK, Bunnage M, Plaha P, Svendsen CN, Heywood P, Gill SS. Intraputamenal infusion of glial cell line-derived neurotrophic factor in PD: a two-year outcome study. Ann. Neurol.57, 298–302 (2005).
   PubMed Web of Science ®Google Scholar
• Lang AE, Gill S, Patel NK et al. Randomized controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson disease. Ann. Neurol.59, 459–466 (2006).
   PubMed Web of Science ®Google Scholar
• Hutchinson M, Gurney S, Newson R. GDNF in Parkinson disease: an object lesson in the tyranny of type II. J. Neurosci. Methods163, 190–192 (2007).
   PubMedGoogle Scholar
• Matcham J, McDermott MP, Lang AE. GDNF in Parkinson’s disease: the perils of post-hoc power. J. Neurosci. Methods163, 193–196 (2007).
   PubMedGoogle Scholar
• Dass B, Olanow CW, Kordower JH. Gene transfer of trophic factors and stem cell grafting as treatments for Parkinson’s disease. Neurology66(10 Suppl. 4), S89–S103 (2006).
   PubMed Web of Science ®Google Scholar
• Freed CR, Leehey MA, Zawada M et al. Do patients with Parkinson’s disease benefit from embryonic dopamine cell transplantation? J. Neurol.250(Suppl. 3) 44–46 (2003).
   Google Scholar
• Mendez I, Sanchez-Pernaute R, Cooper O et al. Cell type analysis of functional fetal dopamine cell suspension transplants in the striatum and substantia nigra of patients with Parkinson’s disease. Brain128, 1498–1510 (2005).
   PubMed Web of Science ®Google Scholar
• Piccini P, Pavese N, Hagell P et al. Factors affecting the clinical outcomes after neural transplantation in Parkinson’s disease. Brain128, 2977–2986 (2005).
   PubMed Web of Science ®Google Scholar
• Winkler C, Kirik D, Björklund A. Cell transplantation in Parkinson’s disease: how can we make it work. Trends Neurosci.28, 86–92 (2005).
   PubMed Web of Science ®Google Scholar
• Apostolides C, Sanford E, Hong M, Mendez I. Glial cell line-derived neurotrophic factor improves intrastriatal graft survival of stored dopaminergic cells. Neuroscience83, 363–372 (1998).
   PubMed Web of Science ®Google Scholar
• Rosenblad C, Martinez-Serrano A, Björklund A. Glial cell line-derived neurotrophic factor increases survival, growth and function of intrastriatal fetal nigral dopaminergic grafts. Neuroscience75, 979–985 (1996).
   PubMed Web of Science ®Google Scholar
• Mehta V, Hong M, Spears J, Mendez I. Enhancement of graft survival and sensorimotor behavioral recovery in rats undergoing transplantation with dopaminergic cells exposed to glial cell line-derived neurotrophic factor. J. Neurosurg.88, 1088–1095 (1998).
   PubMed Web of Science ®Google Scholar
• Sinclair SR, Svendsen CN, Torres EM, Martin D, Fawcett JW, Dunnett SB. GDNF enhances dopaminergic cell survival and fibre outgrowth in embryonic nigral grafts. Neuroreport7, 2547–2552 (1996).
   PubMed Web of Science ®Google Scholar
• Hebb AO, Hebb K, Ramachandran AC, Mendez I. Glial cell line-derived neurotrophic factor-supplemented hibernation of fetal ventral mesencephalic neurons for transplantation in Parkinson disease: long-term storage. J. Neurosurg.98, 1078–1083 (2003).
   PubMed Web of Science ®Google Scholar
• Borgal L, Hong M, Sadi D, Mendez I. Differential effects of glial cell line-derived neurotrophic factor on A9 and A10 dopamine neuron survival in vitro. Neuroscience147, 712–719 (2007).
   PubMedGoogle Scholar
• Kholodilov N, Yarygina O, Oo TF et al. Regulation of the development of mesencephalic dopaminergic systems by the selective expression of glial cell lineHderived neurotrophic factor in their targets. J. Neurosci.24, 3136–3146 (2004).
   PubMedGoogle Scholar
• Winkler C, Georgievska B, Carlsson T, Lacar B, Kirik D. Continuous exposure to glial cell line-derived neurotrophic factor to mature dopaminergic transplants impairs the graft’s ability to improve spontaneous motor behavior in parkinsonian rats. Neuroscience141, 521–531 (2006).
   PubMed Web of Science ®Google Scholar
• Mendez I, Dagher A, Hong M et al. Enhancement of survival of stored dopaminergic cells and promotion of graft survival by exposure of human fetal nigral tissue to glial cell line-derived neurotrophic factor in patients with Parkinson’s disease. Report of two cases and technical considerations. J. Neurosurg.92, 863–869 (2000).
   PubMed Web of Science ®Google Scholar
• Mendez I, Dagher A, Hong M et al. Simultaneous intrastriatal and intranigral fetal dopaminergic grafts in patients with Parkinson disease: a pilot study. Report of three cases. J. Neurosurg.96, 589–596 (2002).
   PubMed Web of Science ®Google Scholar
• Tatard VM, Sindji L, Branton JG et al. Pharmacologically active microcarriers releasing glial cell line-derived neurotrophic factor: Survival and differentiation of embryonic dopaminergic neurons after grafting in hemiparkinsonian rats. Biomaterials28, 1978–1988 (2007).
   PubMedGoogle Scholar
• Grandoso L, Ponce S, Manuel I et al. Long-term survival of encapsulated GDNF secreting cells implanted within the striatum of parkinsonized rats. Int. J. Pharm.343, 69–78 (2007).
   PubMed Web of Science ®Google Scholar
• Love S, Plaha P, Patel NK, Hotton GR, Brooks DJ, Gill SS. Glial cell line-derived neurotrophic factor induces neuronal sprouting in human brain. Nat. Med.11(7), 703–704 (2005).
   PubMed Web of Science ®Google Scholar
• Slevin JT, Gerhardt GA, Smith CD, Gash DM, Kryscio R, Young B. Improvement of bilateral motor functions in patients with Parkinson disease through the unilateral intraputaminal infusion of glial cell line-derived neurotrophic factor. J. Neurosurg.102, 216–222 (2005).
   PubMed Web of Science ®Google Scholar
• Chebrolu H, Slevin JT, Gash DA et al. MRI volumetric and intensity analysis of the cerebellum in Parkinson’s disease patients infused with glial-derived neurotrophic factor (GDNF). Exp. Neurol.198, 450–456 (2006).
   PubMedGoogle Scholar
• Slevin JT, Gash DM, Smith CD et al. Unilateral intraputamenal glial cell line-derived neurotrophic factor in patients with Parkinson disease: response to 1 year of treatment and 1 year of withdrawal. J. Neurosurg.106, 614–620 (2007).
   PubMed Web of Science ®Google Scholar
• Tatarewicz SM, Wei X, Gupta S, Masterman D, Swanson SJ, Moxness MS. Development of a maturing T-cell-mediated immune response in patients with idiopathic Parkinson’s disease receiving r-metHuGDNF via continuous intraputaminal infusion. J. Clin. Immunol.27, 620–627 (2007).
   PubMed Web of Science ®Google Scholar